

News Releases

All Years



Search

GO

[Advanced Search](#)

Apr 17, 2019

Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019

SOUTH SAN FRANCISCO, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company'

Mar 20, 2019

Portola Pharmaceuticals' Co-Founder Dr. Charles Homcy Retires from the Company's Board of Directors

SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his...

Mar 6, 2019

Portola Pharmaceuticals to Webcast Presentation at Cowen and Company's 39th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola's president and chief executive...

Mar 1, 2019

European CHMP Adopts Positive Opinion on Ondexxys™ (andexanet alfa) Portola Pharmaceuticals' Factor Xa Inhibitor Reversal Agent

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Mar 1, 2019

Portola Pharmaceuticals Enters into \$125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management

Agreement Provides Financial Flexibility for the Ongoing Commercialization of Andexxa® and Launch Preparations in Europe

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it has entered into a \$125 million loan agreement with...

Show 5 per page

[<](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) ... [49](#) [>](#)

